Loading clinical trials...

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION | Clinical Trials | Clareo Health

RECRUITINGPHASE1

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Non-arteritic Ischemic Optic Neuropathy

NCT05147701•The Foundation for Orthopaedics and Regenerative Medicine

View on ClinicalTrials.gov

Summary

This trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of non-arteritic ischemic optic neuropathy

Detailed Description

This patient funded trial aims to study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for the treatment of non-arteritic ischemic optic neuropathy. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy. For patients with more severe disease an autologous Effector cells (activated lymphocytes) treatment will be utilized created from the patient's own cells obtained by apheresis.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of NAION (non-arteritic ischemic optic neuropathy)
•Understanding and willingness to sign a written informed consent document

Exclusion Criteria

•Active infection
•Active cancer
•Chronic multisystem organ failure
•Pregnancy
•Clinically significant Abnormalities on pre-treatment laboratory evaluation
•Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
•Continued drug abuse
•Pre-menopausal women not using contraception
•Previous organ transplant
•Hypersensitivity to sulfur

Locations (2)

Medical Surgical Associates Center

St John's, Antigua and Barbuda

Center for Investigation in Tissue Engineering and Cellular Therapy

Buenos Aires, Argentina

Key Dates

Start Date

February 1, 2022

Primary Completion Date

January 1, 2026

Completion Date

January 1, 2026

Last Updated

April 17, 2025

Enrollment

ESTIMATED participants

Conditions

Eye DiseasesRetinitis PigmentosaDiabetic RetinopathyMacular DegenerationTraumatic Optic NeuropathyOptic Atrophy

Interventions

AlloRx

BIOLOGICAL

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

NCT05926583

Retinitis Pigmentosa

View study

RECRUITINGPHASE2

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

NCT07174726

X-Linked Retinitis Pigmentosa (XLRP)

View study

RECRUITINGNA

Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION

Inclusion Criteria

Exclusion Criteria

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital

Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

CNGB1 and Allied Disorders